Address
275 Shoreline Drive
Redwood City, CA 94065
United States of America (the)
Phone
650 206 4507
Website
Sector
Healthcare
Industry
Biotechnology
Employees
58
First IPO Date
January 14, 2013
| Name | Title | Pay | Year Born |
| Nevan Charles Elam | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board | 1.08M | 1967 |
| Sunil Karnawat | Chief Commercial Officer | 678,804 | 1968 |
| Daron G. Evans | Chief Financial & Business Officer | 738,049 | 1974 |
| Brian Kenneth Roberts | Chief Medical Officer | 767,526 | 1976 |
| Erin O'Boyle | Senior Vice President & Head of Clinical Operations | 0 | N/A |
| Melissa Quinn | Senior Director of People and Culture | 0 | N/A |
| Gopal Saha MBBS | Senior Vice President of Global Clinical Development | 0 | N/A |
| Raj Agrawal | Vice President & Head of Ophthalmological Clinical Development | 0 | N/A |
| Robyn Sweinhart | Vice President & Head of Quality | 0 | N/A |
| Susan Stewart | Chief Regulatory Officer | 0 | 1961 |
| Chris Milks | Vice President & Head of Finance | 0 | N/A |
| Davelyn Eaves Hood | Director and Head of Scientific & Patient Affairs | 0 | N/A |
| Michael Covarrubias | Senior Vice President & Head of Program & Portfolio Management | 0 | N/A |
| Michael R. Deperro | Senior VP & Head of Operations | 0 | N/A |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.